There are currently 15 active clinical trials seeking participants for Plaque Psoriasis research studies. The states with the highest number of trials for Plaque Psoriasis participants are California, Texas, Ontario and Florida.
Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis
NCT04036188
Recruiting
These studies are designed to assess the synergistic efficacy of topical 0.1% triamcinolone cream paired with 40,000 IU of oral vitamin D3 daily in treating mild to moderate psoriasis. The study is designed to have all subjects treated with triamcinolone cream (TAC) for 4 weeks, then will be randomized 1:1 into vitamin D3 or placebo for an additional 12 weeks. At that time, the study will become open-label and all subjects will be placed on (or continue) vitamin D3 for an additional 12 weeks. Th... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/01/2024
Locations: Wright State Physicians, Fairborn, Ohio
Conditions: Plaque Psoriasis, Vitamin D3
Register for Updates
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
NCT06143878
Recruiting
The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Medical Dermatology Specialists, Phoenix, Arizona +163 locations
Conditions: Plaque Psoriasis
Register for Updates
A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT06176768
Recruiting
The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/17/2024
Locations: Dermatology Research Associates, Los Angeles, California +11 locations
Conditions: Plaque Psoriasis
Register for Updates
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
NCT06088199
Recruiting
The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
05/15/2024
Locations: Affiliated Dermatology, Scottsdale, Arizona +25 locations
Conditions: Plaque Psoriasis
Register for Updates
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
NCT06088043
Recruiting
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 56 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Saguaro Dermatology Associates, LLC - Probity - PPDS, Phoenix, Arizona +53 locations
Conditions: Plaque Psoriasis
Register for Updates
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
NCT06108544
Recruiting
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 69 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Total Skin and Beauty Dermatology Center, Birmingham, Alabama +84 locations
Conditions: Plaque Psoriasis
Register for Updates
Topical SGX302 for Mild-to-Moderate Psoriasis
NCT05442190
Recruiting
To evaluate SGX302 (topical hypericin ointment) with visible light in an initial 18-week treatment course for improving lesions in patients with mild-to-moderate psoriasis.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/23/2024
Locations: Therapeutics Clinical Research, San Diego, California
Conditions: Psoriasis, Plaque Psoriasis, Psoriasis Vulgaris
Register for Updates
Bimekizumab in Plaque Psoriasis
NCT06336343
Recruiting
The purpose of this research study is to evaluate the effectiveness and safety of bimekizumab in individuals with moderate-to-severe psoriasis who have failed similar therapies. Bimekizumab improves psoriasis by suppressing a type of substance found in bodies called interleukins (specifically, interleukins 17a and 17F), which are known to increase inflammation. This study will look at the effectiveness of bimekizumab in psoriasis patients that have failed previous therapies that target interleuk... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Windsor Dermatology - Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey +1 locations
Conditions: Plaque Psoriasis
Register for Updates
Guselkumab Immunogenetics
NCT04645355
Recruiting
This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/06/2024
Locations: UCSF Psoriasis and Skin Treatment Center, San Francisco, California
Conditions: Psoriasis Guttate, Plaque Psoriasis
Register for Updates
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
NCT04846959
Recruiting
The objective of this registry is to compare outcomes of risankizumab-exposed pregnancies with those of pregnancies that were not exposed to risankizumab among women with plaque psoriasis, psoriatic arthritis (PsA), Crohn's disease (CD), or other conditions for which risankizumab is an FDA-approved treatment. The registry is designed to estimate the association between risankizumab and maternal, fetal, and infant outcomes by comparing the prevalence rates of these outcomes in the exposed and une... Read More
Gender:
Female
Ages:
All
Trial Updated:
03/05/2024
Locations: Evidera, a PPD Business Unit /ID# 238688, Morrisville, North Carolina +1 locations
Conditions: Plaque Psoriasis, Psoriatic Arthritis, Crohn Disease, Other Conditions for Which Risankizumab is an FDA-approved Treatment
Register for Updates
Role of Insulin Action in Psoriasis Pathogenesis
NCT06242847
Recruiting
The goal of this study is to collect more information from people with plaque psoriasis and to determine if insulin plays a role in the pathogenesis of psoriasis. The main question it aims to answer is if insulin action is preserved or even enhanced in psoriatic lesions despite insulin resistance elsewhere. Participants with plaque psoriasis will have punch biopsies taken of lesional and non-lesional skin after an overnight fast and then during an oral glucose tolerance test. Biopsy specimens wi... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
01/29/2024
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Psoriasis, Plaque Psoriasis, Insulin Resistance, PreDiabetes, Overweight and Obesity
Register for Updates
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis
NCT05772520
Recruiting
This is a Phase 2, multicenter, randomized, double-blinded, parallel dose group, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of 3 doses of TLL018 as therapy in 120 participants with moderate-to-severe PP.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
09/20/2023
Locations: Cahaba, Birmingham, Alabama +25 locations
Conditions: Plaque Psoriasis
Register for Updates